Insiders Make Huge Buys in Gold Miners and More
In the past week, a couple of gold-mining stocks attracted the attention of insider buyers. Billionaire hedge fund manager John Paulson was a huge insider buyer this past week.
Headquartered in Redwood City, CA Fiscal year ends December NASDAQ: CDXS codexis.com
Codexis, Inc. provides enzymatic solutions for manufacturing complex therapeutics.
Its BioCatalysis business supplies high-performance engineered enzymes used to manufacture multiple commercially available small-molecule drugs. This business generates product revenue, which recently grew as customers approved and launched new, higher-margin products. The company also earns research and development revenue from collaborations.
Its main development focus is the proprietary ECO Synthesis Manufacturing Platform. This aqueous enzymatic process is intended as a scalable alternative to traditional solid-phase chemical synthesis of oligonucleotides. It is initially aimed at RNAi and siRNA therapeutics, with potential benefits including:
- Higher yields and purity
- Control of stereoisomers
- Reduced energy use and waste
- Lower capital requirements
Codexis is working with siRNA drug innovators, including through feasibility studies, and with contract development and manufacturing organizations (CDMOs). It plans to build an ECO GMP Manufacturing Center to supply siRNA material for preclinical and Phase 1/2 clinical trials. Updated
In the past week, a couple of gold-mining stocks attracted the attention of insider buyers. Billionaire hedge fund manager John Paulson was a huge insider buyer this past week.
So far in June, some insiders have made colossal purchases of shares of their companies. This big insider buying came largely from beneficial owners.
Toyota has made a huge purchase of shares in an air mobility company. However, it was not the only huge insider buying recently.
These five stocks that Cathie Wood's ARK funds own millions of shares of are perfect for aggressive investors who look to get share count leverage on companies that have sizable upside potential.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including AstraZeneca, Bumble, McDonald’s and Microsoft.
The top analyst upgrades, downgrades and other research calls from Wednesday include ADP, Broadcom, Vale, VMware, Walgreens and Zebra Technologies.
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Abercrombie & Fitch, Altria, Anthem, United Continental, Blackstone and AMAG Pharmaceuticals.
With the markets at or near record highs, the volume of insider selling has reached some of the highest levels this year.
Shares of KiOR slipped to an all-time low of $0.60 a share Tuesday after it filed its annual report with the U.S. Securities and Exchange Commission, a report in which it raised…
August 9, 2013: U.S. equity markets opened lower this morning and bounced around below the break-even line most of the day. The day’s biggest economic news came from China, where the CPI…
U.S. equity markets opened lower this morning, kicking off a gradual decline that lasted all day. Profit-taking and a lower-than-expected reading on consumer sentiment in the U.S. get the blame. In Europe,…
ThinkstockThe U.S. Environmental Protection Agency (EPA) yesterday proposed new rules and percentage standards for 2013 biofuel consumption. The agency wants U.S. drivers to use 16.55 billion gallons (about 394 million barrels) of…
Any tax legislation worth the name carries with it a host of hangers on that represent special gifts to special interests. The American Taxpayer Relief Act of 2012 is no different. Here…
The three major US stock indexes opened lower this morning following more data from China. Both export and import data fell short, weighing on most Asian markets (more coverage here). There was…
The three major US stock indexes opened mixed this morning following a wealth of data on the Chinese economy. The short version is that the economy is slowing so much and inflation…
Codexis, Inc. provides enzymatic solutions for manufacturing complex therapeutics. Its BioCatalysis business supplies high-performance engineered enzymes used to manufacture multiple commercially available small-molecule drugs.
The Wall Street consensus 12-month price target for CDXS is $6.14.